Stockscreener 앱 받기
31.70
4.14%
1.26
시장 영업 전:
32.90
1.20
+3.79%
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Best Momentum Stock to Buy for August 8th - MSN
Rigel targets up to $280M 2025 revenue as IRA boosts sales and pipeline advances - MSN
Is Rigel Pharmaceuticals Inc. a candidate for recovery playPredictable Entry Strategy With Technical Backing - Newser
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy? - Yahoo Finance
Top 5 Stocks with Strong Price Performance to Buy Now - AInvest
5 Best Stocks With Relative Price Strength to Buy Right Now - sg.finance.yahoo.com
Results: Rigel Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
New Strong Buy Stocks for August 8th - TradingView
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2025 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals Flips To A Profit On Rising Sales - Finimize
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Citi Analysts Maintain Buy Rating on Rigel with $67 Price Target - AInvest
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates - MSN
Rigel Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $67 - 富途牛牛
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals (NASDAQ:RIGL) Shareholder Returns Have Been Solid, Earning 160% in 1 Year - 富途牛牛
Cantor Fitzgerald Raises Price Target for RIGL to $32.00, Mainta - GuruFocus
Rigel Pharmaceuticals shares surge 16.67% intraday after strong Q2 earnings and revenue guidance. - AInvest
Rigel Pharmaceuticals: Cantor Fitzgerald Maintains Neutral, PT Raised to $32 from $23. - AInvest
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28% - simplywall.st
Rigel (RIGL) Q2 Revenue Jumps 176% - The Globe and Mail
Rigel (RIGL) Q2 Revenue Jumps 176% - The Motley Fool
Jefferies raises Rigel Pharmaceuticals stock price target on strong sales By Investing.com - Investing.com Nigeria
Jefferies raises Rigel Pharmaceuticals stock price target on strong sales - Investing.com
RIGL files S-8 to register 825,000 shares for employee equity plans | RIGL SEC FilingForm S-8 - Stock Titan
Rigel Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Rigel: Q2 Earnings Snapshot - New Haven Register
Rigel Pharmaceuticals Exceeds Q2 2025 Revenue Guidance with 76% YoY Increase - AInvest
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlight - GuruFocus
Rigel Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Rigel Pharmaceuticals' Q2 2025: Unpacking Contradictions in Tavalisse Growth and GAVRETO Sales Dynamics - AInvest
Rigel Pharmaceuticals Sets Ambitious 2025 Revenue Target of $280M as IRA Boosts Sales and Pipeline Advances - AInvest
Rigel Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL): A High-Growth Biotech Play with a Self-Funding Pipeline and Expanding Global Reach - AInvest
Earnings call transcript: Rigel Pharmaceuticals Q2 2025 boosts guidance, stock rises - Investing.com India
Earnings call transcript: Rigel Pharmaceuticals Q2 2025 boosts guidance, stock rises By Investing.com - Investing.com South Africa
RIGL Updates FY25 Revenue and Sales Projections - GuruFocus
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rigel Pharmaceuticals' Q2 Earnings Momentum and Analyst Optimism: Assessing the Sustainability of Outperformance for Long-Term Investors - AInvest
Rigel Pharmaceuticals reports Q2 EPS $3.91, consensus $1.40 - TipRanks
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
RIPK1 Inhibitor Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Sanofi, Genfleet Therapeutics, Rigel Pharma, GlaxoSmithKline, AbbVie, Sanofi - The Globe and Mail
Silvercorp Announces Ecuador Constitutional Court Decision Upholding Environmental License for El Domo Project - The Globe and Mail
Canada Nickel Releases 2024 ESG Report - The Globe and Mail
Rigel Pharmaceuticals Receives IBD Stock Rating Upgrade - inkl
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Candlestick Reversal Detected on Rigel Pharmaceuticals Inc.’s ChartReversal Alert Based on RSI Indicator Confirmed - beatles.ru
What makes Rigel Pharmaceuticals Inc. stock price move sharplyMaximize returns with effective portfolio management - Jammu Links News
What institutional investors are buying Rigel Pharmaceuticals Inc. stockDiscover market opportunities with real-time data - Jammu Links News
What analysts say about Rigel Pharmaceuticals Inc. stockReal-time trading signals for maximum returns - Jammu Links News
Should I hold or sell Rigel Pharmaceuticals Inc. stock in 2025Rapid portfolio appreciation - Jammu Links News
Is Rigel Pharmaceuticals Inc. a good long term investmentBuild a winning investment portfolio - Jammu Links News
Why is Rigel Pharmaceuticals Inc. stock attracting strong analyst attentionExplosive portfolio gains - Jammu Links News
How strong is Rigel Pharmaceuticals Inc. company’s balance sheetDiscover high-return stocks for your portfolio - Jammu Links News
Rigel Pharmaceuticals (RIGL): Navigating Institutional Ownership and Stock Price Volatility in 2025 - AInvest
0.24%
3.39%
자본화:
|
볼륨(24시간):